摘要
高剂量治疗(HDT)后自体干细胞移植(ASCT)仍然是年龄在65岁以下多发性骨髓瘤(MM)患者的护理标准。然而这种治疗方法在过去十年中已经取得了重大进展,主要是由于引入了新药,如沙利度胺,来那度胺和硼替佐米。这些不同组合的新药显示出在诱导治疗和ASCT后显著提高了应答率。此外,ASCT在巩固和维护策略中获得的积极成果强烈支持持续治疗的概念,其最终目标是对疾病的长期控制和治疗结果的改善。调查下一代蛋白酶体抑制剂(如卡菲霉素和ixazomib)的研究的初步数据在前期以及随后的治疗线路中使用,显示了在大多数患者中获得分子缓解的可能性。通过新的药物组合获得的更深层次的反应质疑了ASCT的作用,大量正在进行的第3阶段试验将揭示ASCT的作用和时机。
关键词: 干细胞移植,多发性骨髓瘤,ASCT,蛋白酶体抑制剂,carfilzomib,ixazomib
图形摘要
Current Cancer Drug Targets
Title:Stem Cell Transplantation in Multiple Myeloma
Volume: 17 Issue: 9
关键词: 干细胞移植,多发性骨髓瘤,ASCT,蛋白酶体抑制剂,carfilzomib,ixazomib
摘要: High-dose therapy (HDT) followed by autologous stem cell transplantation (ASCT) remains the standard of care for patients younger than 65 years of age with multiple myeloma (MM). However, this therapeutic approach has undergone substantial advances in this last decade, mainly due to the introduction of new drugs such as thalidomide, lenalidomide and bortezomib. These new drugs, in different combinations, have shown to significantly increase response rates after induction therapy and ASCT. Moreover, the positive results obtained with these agents in consolidation and maintenance strategies after ASCT strongly support the concept of continuous therapy, whose ultimate goal is the long-term control of the disease and the improvement of outcome. Preliminary data from studies investigating next generation proteasome inhibitors, such as carfilzomib and ixazomib, used upfront as well as at subsequent therapeutic lines, demonstrate the possibility of achieving molecular remission in most of the patients. The deeper responses obtained with new drugcombinations questioned the role of ASCT, and large, ongoing, phase 3 trials will shed light on the role and the timing of ASCT.
Export Options
About this article
Cite this article as:
Stem Cell Transplantation in Multiple Myeloma, Current Cancer Drug Targets 2017; 17 (9) . https://dx.doi.org/10.2174/1568009616666160920090236
DOI https://dx.doi.org/10.2174/1568009616666160920090236 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pharmacological Profile and Pharmacogenomics of Anti-Cancer Drugs Used for Targeted Therapy
Current Cancer Drug Targets Novel Therapeutic Agents Against Cancer Stem Cells of Chronic Myeloid Leukemia
Anti-Cancer Agents in Medicinal Chemistry Chemistry and Biological Activity of [1,2,3]-Benzotriazine Derivatives
Current Organic Chemistry Nano-Delivery in Pediatric Tumors: Looking Back, Moving Forward
Anti-Cancer Agents in Medicinal Chemistry Haploinsufficiency of DNA Damage Response Genes and their Potential Influence in Human Genomic Disorders
Current Genomics ACE Inhibitors and AII Receptor Antagonists in the Treatment and Prevention of Bone Marrow Transplant Nephropathy
Current Pharmaceutical Design Development of RGD-Based Radiotracers for Tumor Imaging and Therapy: Translating from Bench to Bedside
Current Molecular Medicine Notch Signaling Proteins: Legitimate Targets for Cancer Therapy
Current Protein & Peptide Science Impact of HIV on Regional & Cellular Organisation of the Brain
Current HIV Research Encapsulation of Imatinib in Targeted KIT-5 Nanoparticles for Reducing its Cardiotoxicity and Hepatotoxicity
Anti-Cancer Agents in Medicinal Chemistry Antidepressant Desipramine Leads to C6 Glioma Cell Autophagy: Implication for the Adjuvant Therapy of Cancer
Anti-Cancer Agents in Medicinal Chemistry Paving Roads for New Drugs in Oncology
Recent Patents on Anti-Cancer Drug Discovery Structure-based Drug Design Strategies in the Development of Small Molecule Inhibitors Targeting Bcl-2 Family Proteins
Letters in Drug Design & Discovery Manipulation of Intracellular pH in Cancer Cells by NHE1 Inhibitors
Protein & Peptide Letters Gene Therapy Strategies Towards Immune Tolerance to Treat the Autoimmune Diseases
Current Gene Therapy Multifaceted Role of Neuropilins in Cancer
Current Medicinal Chemistry Spermine Metabolism and Anticancer Therapy
Current Cancer Drug Targets CEBP Epigenetic Dysregulation as a Drug Target for the Treatment of Hematologic and Gynecologic Malignancies
Current Drug Targets Recent Developments to Improve the Efficacy of Cytotoxic Nucleoside Analogues
Recent Patents on Anti-Cancer Drug Discovery T Lymphocytes as Targets of Gene Transfer with Moloney-Type Retroviral Vectors
Current Gene Therapy